Photo from academic.microsoft.com
The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular… Click to show full abstract
The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.
Keywords:
effects dulaglutide;
renoprotective effects;
t2dm ckd;
patients t2dm;
dulaglutide patients
Journal Title: Nature Reviews Nephrology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Nephrology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!